iBio (IBIO) Cash & Equivalents (2010 - 2026)

iBio (IBIO) has 17 years of Cash & Equivalents data on file, last reported at $47.6 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 852.62% year-over-year to $47.6 million in Q1 2026; TTM through Mar 2026 was $47.6 million, a 852.62% increase from a year earlier, with the FY2025 full-year figure at $8.6 million, down 39.61% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $47.6 million, up from $28.7 million in the prior quarter.
• Over the last five years, Cash & Equivalents for IBIO reached as high as $47.6 million in Q1 2026 and fell as low as $1.5 million in Q3 2023.
• Historically, Cash & Equivalents has averaged $14.2 million across 5 years, with a median of $8.6 million in 2025.
• Across the five-year window, Cash & Equivalents slumped 90.57% in 2022 and soared 852.62% in 2026, its largest moves.
• Year by year, Cash & Equivalents stood at $3.7 million in 2022, then declined by 24.57% to $2.8 million in 2023, then jumped by 151.61% to $7.0 million in 2024, then jumped by 308.72% to $28.7 million in 2025, then surged by 66.12% to $47.6 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $47.6 million in Q1 2026, $28.7 million in Q4 2025, and $28.1 million in Q3 2025.